ILEAL BIOMARKER OF INNATE IMMUNE ACTIVATION CAN PREDICT CLINICAL RESPONSE TO VEDOLIZUMAB IN CROHN'S DISEASE

被引：0
|
作者：
Osterman, Mark T.
Gordon, Ilyssa O.
Davis, Elisabeth M.
Ciorba, Matthew A.
Glover, Sarah C.
Abraham, Bincy P.
Khan, Freeha
Shen, Bo
Yee, Eric
Allard, Felicia
Liu, Julia J.
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 03期
关键词：
D O I：
10.1053/j.gastro.2019.01.148
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P087
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 50 条
  • [31] A Combination of Genetic, Clinical and Immune Markers Predict the Need for Surgery in Crohn's Disease
    Dubinsky, Marla
    Kugathasan, Subra
    Kwon, Soonil
    Haritunians, Talin
    Wrobel, Iwona T.
    Wahheh, Ghassan
    Quims, Antonio
    Hahar, Ron J.
    Farrior, Sharmayne
    Teleten, Nick
    Panikkath, Deeps
    Ippoliti, Andrew
    Fleshner, Phillip
    Williams, Chadwick I.
    Landers, Carol J.
    Targan, Stephan R.
    Rutter, Jerome I.
    Taylor, Kent D.
    McGovern, Dermot P.
    GASTROENTEROLOGY, 2011, 140 (05) : S153 - S153
  • [32] Ultrasound Characteristics Can Predict Response to Biologics Therapy in Stricturing Crohn's Disease
    Ma, Li
    He, Yudi
    Li, Wenbo
    Xiao, Mengsu
    Zhou, Mengyuan
    Qin, Jing
    Yang, Hong
    Liu, Wei
    Zhu, Qingli
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2024, 15 (08)
  • [33] Characterization of clinical phenotypes of Crohn's disease of the ileal pouch
    Shen, Bo
    Fazio, Victor
    Remzi, Feza
    Bennett, Ana
    Lopez, Rocio
    Brzezinski, Aaron
    Achkar, Jean-Paul
    Oikonomou, Ioannis
    Sherman, Kerry
    Bambrick, Marlene
    Lashner, Bret
    GASTROENTEROLOGY, 2006, 130 (04) : A651 - A651
  • [34] Crohn's disease recurrence can be prevented after ileal resection
    Rampton, DS
    GUT, 2002, 51 (02) : 153 - 154
  • [35] Can Stenosis in Ileal Crohn's Disease Be Prevented by Current Therapy?
    Limketkai, Berkeley N.
    Bayless, Theodore M.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 (11): : 1755 - 1756
  • [36] Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease
    Alric, Hadrien
    Amiot, Aurelien
    Kirchgesner, Julien
    Treton, Xavier
    Allez, Mathieu
    Bouhnik, Yoram
    Beaugerie, Laurent
    Carbonnel, Franck
    Meyer, Antoine
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (02) : 218 - 225
  • [37] Vedolizumab for the Treatment of Crohn's Disease: Experience in an Inflammatory Bowel Disease Clinical Practice
    Blum, Andrew
    Nizialek, Gregory
    Parikh, Keyur
    Dave, Maneesh
    Katz, Jeffry
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S276 - S276
  • [38] ILEAL OR COLONIC HISTOLOGIC ACTIVITY DOES NOT PREDICT CLINICAL RELAPSE IN PATIENTS WITH CROHN'S DISEASE IN ENDOSCOPIC REMISSION
    Hu, Anne
    Tan, William
    Deshpande, Vikram
    Ananthakrishnan, Ashwin
    GASTROENTEROLOGY, 2020, 158 (06) : S692 - S692
  • [39] Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease After Immune Checkpoint Inhibitors
    Zarker, Andrew W.
    Wang, Yinghong
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S2533 - S2534
  • [40] Combination vedolizumab and ustekinumab for refractory Crohn's disease after immune checkpoint inhibitors
    Zarker, Andrew W.
    Wang, Yinghong
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 37 (02) : 240 - 241
12345